KalVista Posts 154% Expense Jump in Q1

KalVista Pharmaceuticals reported Q1 FY2026 results, marking its transition to a commercial-stage company with the U.S. launch of EKTERLY (sebetralstat), an oral HAE treatment. The drug generated $1.4 million in initial revenue, and early patient uptake exceeded expectations with 460 start forms in eight weeks. However, commercialization efforts drove SG&A expenses to $44.7 million, widening the net loss to $60.1 million. Despite increased costs, EKTERLY secured FDA and UK approvals, with a positive European CHMP opinion expected to lead to a final marketing decision in October, bolstering its market exclusivity. KalVista ended the quarter with $191.5 million in cash, providing a runway into 2027 as it focuses on prescription conversion, payer reimbursement, and international expansion.

Analysis

KalVista Pharmaceuticals has successfully transitioned into a commercial-stage entity with the U.S. launch of EKTERLY, its first-in-class oral therapy for hereditary angioedema (HAE). The launch demonstrated strong early market traction, generating $1.4 million in initial revenue and securing 460 patient start forms within eight weeks, representing nearly 5% of the estimated U.S. patient population. However, this commercial push drove a 154% year-over-year increase in SG&A expenses to $44.7 million, significantly widening the quarterly net loss to $60.1 million. The company's cash position decreased by $29.1 million during the quarter to $191.5 million, though management maintains a cash runway into 2027, supported by a 43% reduction in R&D spending as focus shifts. The outlook is further bolstered by key regulatory milestones, including U.K. approval and a positive CHMP opinion in Europe, which signals a probable EU marketing authorization in October 2025 and grants up to 10 years of market exclusivity. The central tension for investors lies between the drug's promising early uptake and the substantial, ongoing cash burn required for commercialization, with the key unknown being the conversion rate of initial patient interest into sustained, revenue-generating prescriptions.

Key Decisions for Investors

• Investors should closely monitor the conversion rate of the 460 patient start forms into recurring, filled prescriptions, as this is the primary metric for validating the commercial model and justifying the high SG&A spend.
• Given the quarterly cash burn of approximately $29 million, it is prudent to evaluate management’s ability to control commercialization costs as sales scale to ensure the stated cash runway into 2027 remains viable.
• The anticipated European Commission marketing decision in October 2025 represents a significant near-term catalyst that could de-risk the international expansion strategy and open a major new market, potentially bolstering the long-term revenue outlook.